Development of a Tailored Life-Sustaining Treatment Decision Support Intervention for Stroke Surrogate Decision Makers
The trial is testing an investigator-developed decision support tool for surrogate decision makers for stroke patients that are unable to make medical decisions for themselves.
A historical usual care control group will be enrolled during tool development. The tool will then be tested in surrogates of hospitalized stroke patients.
연구 개요
상세 설명
Decision support tools, specifically recommended in the 2010 Affordable Care Act, have been shown to improve the quality of decisions and reduce burden on the decision maker in multiple clinical settings, yet almost none have focused on life-sustaining treatments in acute critical illness such as stroke. This study proposes a comprehensive frame shift in how the health care team and surrogates collaborate on decisions regarding life-sustaining treatments for acute illness, by developing a tailored web-based stroke decision support intervention. This web-based tool will be developed for use by the surrogate decision maker during the acute stroke hospitalization and will be designed to facilitate high quality patient-centered decisions and minimize adverse effects on the surrogate.
The two project phases are: 1) Decision support intervention development; and 2) Pilot testing in surrogates of hospitalized stroke patients. A novel ordinal prognostic model will be developed and incorporated into the tool.
The project expects 25 surrogate-patient pairs in the control group, and 25 surrogate-patient pairs in the intervention group, which equals a total of 100 subjects.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- The University of Michigan
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Surrogates:
Inclusion Criteria:
- Self-identify as the surrogate decision maker for eligible patient
- Able to read and communicate in English without an interpreter
- Limited to one surrogate per patient
Exclusion Criteria:
- No prior relationship with patient
- Dementia or other cognitive or health condition that would impair their ability to participate
Patients:
Inclusion Criteria:
- Ischemic stroke or spontaneous intracerebral hemorrhage
- Impaired decisional capacity (per treating team)
- Enrolled on or before full hospital day 5
Minimum illness severity (either):
- National Institutes of Health Stroke Scale ≥ 10
- Glasgow coma scale ≤12
Exclusion Criteria:
- No surrogate available for study procedures
- Already on comfort measures only
- Physician refuses to allow approach for consent
- Pregnancy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
간섭 없음: Control Surrogate Arm
Usual care control group will complete baseline and follow-up questionnaires with standard decision making techniques.
This group will not be asked to use the decision making tool.
|
|
|
실험적: Surrogate Decision Tool Arm
This group will complete a baseline questionnaire, then use the tool and complete follow up questionnaires.
|
A tailored web-based stroke decision support intervention.
This web-based tool will be developed for use by the surrogate decision maker during the acute stroke hospitalization and will be designed to facilitate high quality patient-centered decisions and minimize adverse effects on the surrogate.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Acceptability of the decision tool intervention
기간: Immediately post-intervention
|
The proportion of cases where the surrogate completes use of the tool with high acceptability using the Acceptability E-Scale.
The Acceptability E-Scale is a 6-item scale.
A score of 1 indicates a negative evaluation and 5 indicates a positive evaluation.
A score of 3 indicates a neutral evaluation.
An individual will be considered to have high acceptability if the average response across the 6 items is 4 or higher)
|
Immediately post-intervention
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Accuracy of the surrogate's prognostic estimate for functional recovery
기간: Within approximately 5 days of admission
|
Calculated as the absolute value of the difference between the surrogate's estimate of the probability (0-100%) of return to functional independence by 90 days and the model based estimate of modified Rankin of 0-2.
Range of this measure will be 0-100.
|
Within approximately 5 days of admission
|
|
Decisional Self Efficacy scale
기간: Within approximately 5 days of admission
|
11-item scale (a score of 0 indicates not at all confident and a 4 indicates very confident) with ordered categorical responses, converted to a 0-100 scale based on the average of the responses to each item.
A score of 0 means extremely low self-efficacy and a score of 100 means extremely high self-efficacy
|
Within approximately 5 days of admission
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Darin Zahuranec, University of Michigan
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
뇌졸중에 대한 임상 시험
-
Institut National de la Santé Et de la Recherche...모병
Decision tool에 대한 임상 시험
-
Necmettin Erbakan UniversityKonya City Hospital모병
-
University of Alabama at BirminghamNational Cancer Institute (NCI)모집하지 않고 적극적으로
-
University of PittsburghNational Institute on Minority Health and Health Disparities (NIMHD); University of California... 그리고 다른 협력자들완전한
-
University of Alabama at Birmingham완전한
-
San Diego State UniversityUniversity of California, San Francisco초대로 등록
-
Oslo University HospitalThe Research Council of Norway완전한림프종 | 백혈병 | 암 | 줄기세포 이식
-
Tan Tock Seng HospitalMarquette University; Lee Kong Chian School of Medicine, Nanyang Technological University아직 모집하지 않음
-
Zhu Dian완전한
-
Massachusetts General Hospital완전한